Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLuca LaninoGUGeoffrey L. UyPDPinkal Desai

Discussion

Loading...

Member takes

Overview

Analysis shows poor outcomes in high-risk myelodysplastic syndromes with TP53 mutations, suggesting refined risk stratification may guide therapy decisions.

Key Points

  • TP53 mutations were associated with worse overall survival compared to TP53 wild-type patients, emphasizing their prognostic significance.
  • Treatment responses varied, with azacitidine and decitabine being common hypomethylating agents used in the cohort.
  • Molecular clustering identified distinct subgroups, highlighting the complexity of risk stratification in TP53 mutation cases.
  • Higher chromosomal abnormalities were present in TP53 mutations, indicating more aggressive disease in affected patients.

Cite This Study

Lanino et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d845https://doi.org/10.1182/blood-2025-3863
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations
  2. 2Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  3. 3Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy2025
  4. 4Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  5. 5Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies2025